FindTrial
Sign In

Sildosin as a Male Contraceptive Non Hormonal

A Prospective Study to Evaluate the Efficacy of Silodosin 8 mg as an on-Demand, Reversible, Nonhormonal Oral Contraceptive for Males:

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07195097
Enrollment
200
Registered
2025-09-26
Start date
2025-09-30
Completion date
2025-12-31
Last updated
2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception Use

Brief summary

In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.

Interventions

DRUGOral intake of sildosin

Oral intake of sildosin in male non hormonal contraception

OTHEROral intake of placebo

Intake of placebo to compare effecacy of other group

Sponsors

Benha University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* male sexually active

Exclusion criteria

* male on oral contraceptives Male with female partner on contraceptives

Design outcomes

Primary

MeasureTime frameDescription
Pregnancy rate in people treated with sildosin as a male contraceptive3 monthsPregnancy rate in people treated with sildosin as a male contraceptive treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026